Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M D , FACS as Chief Medical Officer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Horizon Therapeutics plc (NASDAQ: HZNP) and
Viela Bio, Inc. (NASDAQ: VIE) have entered into a definitive agreement where Horizon will acquire all issues and outstanding shares of Vielo Bio common stock for USD 53 per share in cash or a fully diluted equity value of USD 3.05 Billion. The transaction is expected to close by the end of the first quarter of 2021. “This acquisition represents a significant step forward in advancing our strategy – to expand our pipeline in order to accelerate our growth over the long term,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “Adding Viela’s research and clinical development capabilities along with its deep, mid-stage biologics pipeline to our seasoned R&D and commercial teams, advances our transformation to an innovation-driven biotech company where we will build on the success of TEPEZZA and KRYSTEXXA to bolster our long-term growth trajectory. We intend to maximize the full potential of Viela’s